Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Cash from Operations (2023 - 2025)

Historic Cash from Operations for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to -$32.8 million.

  • NewAmsterdam Pharma's Cash from Operations fell 16211.01% to -$32.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$144.4 million, marking a year-over-year increase of 633.64%. This contributed to the annual value of -$158.6 million for FY2024, which is 1228.31% down from last year.
  • Latest data reveals that NewAmsterdam Pharma reported Cash from Operations of -$32.8 million as of Q3 2025, which was down 16211.01% from -$37.7 million recorded in Q2 2025.
  • Over the past 5 years, NewAmsterdam Pharma's Cash from Operations peaked at -$12.5 million during Q3 2024, and registered a low of -$54.6 million during Q1 2024.
  • Moreover, its 3-year median value for Cash from Operations was -$36.5 million (2025), whereas its average is -$37.0 million.
  • Per our database at Business Quant, NewAmsterdam Pharma's Cash from Operations surged by 7338.64% in 2024 and then crashed by 16211.01% in 2025.
  • NewAmsterdam Pharma's Cash from Operations (Quarter) stood at -$33.1 million in 2023, then decreased by 13.32% to -$37.5 million in 2024, then grew by 12.57% to -$32.8 million in 2025.
  • Its Cash from Operations was -$32.8 million in Q3 2025, compared to -$37.7 million in Q2 2025 and -$36.5 million in Q1 2025.